|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus显示文摘 | Owonikoko TK Ramalingam SS Belani CP | 2010 | Clin Cancer Res2010，16，9： | 1 |
| 2 | AZD9291, a mutant- selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) :Results from a phase 1 expansion cohort显示文摘 | Ramalingam SS Yang JC Lee CK | 2015 | J Clin Oncol2015，33，15： | 1 |
| 3 | The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer 显示文摘 | Steuer CE Khuri FR Ramalingam SS | 2015 | Carmer2015，121，8： | 1 |
| 4 | Lung cancer:New biological insights and recent therapeutic advances显示文摘 | Ramalingam SS Owonikoko TK Khuri FR | 2011 | CA Cancer J Clin2011，61，2： | 1 |
| 5 | Carbo-platin and paclitaxel in combination with either vorinostat or pla-cebo for first-line therapy of advanced non-small-cell lung cancer显示文摘 | RAMALINGAM SS MAITLAND ML FRANKEL P | 2009 | J Clin Oncol2009，28，1： | 1 |
| 6 | Phase 2 study of irinote-can and paclitaxel in patients with recurrent or refractory small celllung cancer显示文摘 | Ramalingam SS Foster J Gooding W | 2010 | Cancer2010，116，5： | 1 |
| 7 | Lung cancer: new biological insights and recent therapeutic advances 显示文摘 | Ramalingam SS Owonikoko TK Khuri FR | 2011 | CA Cancer J Clin2011，61，2： | 1 |
| 8 | Lung cancer:New biological insights and recent therapeutic advances显示文摘 | Ramalingam SS Owonikoko TK Khuri FR | 2011 | CA Cancer J Clin2011，61，2： | 1 |
| 9 | Lung cancer:New biological insights and recent therapeutic advances显示文摘 | Ramalingam SS Owonikoko TK Khuri FR | | 0，，： | 1 |
| 10 | Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies 显示文摘 | Ramalingam SS Parise RA Ramalingam RK | 2007 | Clin Cancer Res2007，3，： | 1 |
| 11 | Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients ( pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC)显示文摘 | JANNE PA RAMALINGAM SS YANGJC | 2014 | JClinOncol2014，32，5： | 1 |
| 12 | Randomised phaseⅡstudy of dacomitinib(PF-299804),an irreversible pan-human epidermal growth factor receptor inhibitor,versus erlotinib in patients with advanced non-small-cell lung cancer显示文摘 | Ramalingam SS Blackhall F Krzakowski M | 2012 | J Clin Oncol2012，30，27： | 1 |
| 13 | Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097) 显示文摘 | Ramalingam SS Belani CP Mack PC | 2010 | J Thorac Oncol2010，5，8： | 1 |
| 14 | Outcomes for elderly, advanced-stage non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599 显示文摘 | Ramalingam SS Dahlberg SE Langer C J | 2008 | J Clin Oncol2008，26，1： | 1 |
| 15 | Heat shock protein 90 in- hibitors in non-small-cell lung cancer 显示文摘 | Pillai RN Ramalingam SS | 2014 | Curr ()pin On- col2014，26，2： | 1 |
| 16 | Lung cancer: new bi- ological insights and recent therapeutic advances显示文摘 | Ramalingam SS Owonikoko TK Khuri FR | 2011 | CA Cancer J Clin2011，61，2： | 1 |
| 17 | Maintenance therapy for advanced non-small cell lung cancer: current status, controver- sies, and emerging consensus显示文摘 | Owonikoko TK Ramalingam SS Belani CP | 2010 | Clin Cancer Res2010，16，9： | 1 |
| 18 | Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treared with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P):Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study显示文摘 | Ramalingam SS Dahlberg SE Lange CJ | 2007 | J Clin Oncology2007，25，18： | 1 |
| 19 | Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC) : A California Consortium phase Ⅱ study (NCI # 7097 ) 显示文摘 | Ramalingam SS Mack PC Vokes EE | 2008 | J Clin Oncol2008，26，： | 1 |
| 20 | ALK-positive non-small cell lung cancer:mechanisms of resistance and emerging treat- ment options显示文摘 | Steuer CE Ramalingam SS | 2014 | Cancer2014，120，16： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员